Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

• Status: Terminated
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the effectiveness of an investigational treatment for patients with ragweed-induced asthma, sometimes called fall seasonal asthma. The treatment being tested is a series of anti-ragweed shots. The purpose of the study is to determine whether a short series of injections with Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC) can cause a long-lasting reduction in the symptoms of asthma that are caused by fall hay fever allergies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborator: Immune Tolerance Network (ITN)

Criteria

Inclusion Criteria:

• History of asthma

• History of asthma medication use during the 2005 fall ragweed season

• Suspected ragweed allergy

• Positive laboratory tests for ragweed allergy

Exclusion Criteria:

• Received immunotherapy for ragweed or other allergens within the 5 years prior to study entry

• Received anti-IgE (omalizumab) within the year prior to study entry

• 3 or more courses of oral corticosteroids for asthma within the year prior to study entry

• Inpatient hospitalization for asthma within the 5 years prior to study entry

• History of respiratory failure or intubation for asthma

• Smoking within the 6 months prior to study entry

• Greater than 5 pack/year history of smoking

• Clinically significant acute or chronic illness

• Chronic immunodeficiency